Literature DB >> 2821083

Impairment of beta 2-adrenoceptor-stimulated potassium uptake in end-stage renal disease.

C L Stemmer1, G O Perez, J R Oster.   

Abstract

An abnormality of extrarenal mechanisms is believed to contribute importantly to the impaired potassium homeostasis in chronic renal failure. We evaluated the plasma potassium response to inhalation of albuterol, a beta 2 agonist, in eight patients who had end-stage renal disease and who were undergoing chronic hemodialysis and in eight control subjects. The purpose was to assess if an abnormality of the beta 2 adrenoceptor mechanism is present in uremia. The maximal decrement in plasma potassium concentration in the patients (0.12 +/- 0.04 mEq/L) was significantly less than that of the control subjects (0.30 +/- 0.05). Furthermore, the final plasma potassium concentration slightly exceeded baseline in the patients but was significantly reduced in controls, leading to the conclusion that an abnormal responsiveness of the beta 2 adrenoceptor may contribute to the impaired potassium tolerance found in patients who have end-stage renal disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821083     DOI: 10.1002/j.1552-4604.1987.tb03077.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  1 in total

1.  Treatment of hyperkalaemia with intravenous salbutamol.

Authors:  I A Murdoch; R Dos Anjos; G B Haycock
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.